Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
HAE

HAE - Haemonetics Corp Stock Price, Fair Value and News

$59.92+0.43 (+0.72%)
Delayed

51/100

HAE

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

51/100

HAE

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

HAE Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

HAE Price Action

Last 7 days

-6.6%

Last 30 days

4.2%

Last 90 days

-28.2%

Trailing 12 Months

-9.1%

HAE RSI Chart

HAE Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

HAE Valuation

Market Cap

2.8B

Price/Earnings (Trailing)

15.87

Price/Sales (Trailing)

2.11

EV/EBITDA

9.83

Price/Free Cashflow

9.04

HAE Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

HAE Fundamentals

HAE Revenue

Revenue (TTM)

1.3B

Rev. Growth (Yr)

-2.75%

Rev. Growth (Qtr)

3.56%

HAE Earnings

Earnings (TTM)

175.4M

Earnings Growth (Yr)

19.33%

Earnings Growth (Qtr)

15.66%

HAE Profitability

EBT Margin

17.23%

Return on Equity

19.25%

Return on Assets

7.04%

Free Cashflow Yield

11.06%

HAE Investor Care

Buy Backs (1Y)

7.50%

Diluted EPS (TTM)

3.63

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20251.4B1.3B1.3B1.3B
20241.3B1.3B1.4B1.4B
20231.2B1.2B1.2B1.3B
2022993.2M1.0B1.1B1.1B
2021870.5M903.4M933.8M953.2M
2020988.5M945.6M902.5M883.9M
2019967.6M976.7M987.7M999.3M
2018903.9M922.3M938.5M951.8M
2017886.1M887.1M892.2M898.4M
2016908.8M905.4M905.9M900.4M
2015910.4M899.3M891.4M893.0M
2014938.5M943.5M935.3M925.0M
2013892.0M935.1M952.6M947.4M
2012727.8M733.8M772.5M828.7M
2011676.7M684.2M696.8M711.2M
Get all data in R, Python etc through our Historical Stock Data APIs

About Haemonetics Corp

HAE
Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot including collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
 CEO
 WEBSITEhaemonetics.com
 SECTORHealthcare
 INDUSTRYMedical Instruments & Supplies
 EMPLOYEES3034

Haemonetics Corp Frequently Asked Questions

HAE is the stock ticker symbol of Haemonetics Corp. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Mar 13 2026, market cap of Haemonetics Corp is 2.78 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Mar 13 2026, HAE's PE ratio (Price to Earnings) is 15.87 and Price to Sales (PS) ratio is 2.11. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. HAE PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Haemonetics Corp has provided 0.06 (multiply by 100 for percentage) rate of return.